GlycoNex Achieves PMDA Approval for First-in-Human Trial of GNX1021 Targeting Gastrointestinal Cancers GlycoNex, Inc. marks a significant milestone with PMDA approval for GNX1021, initiating its first human trial targeting advanced gastrointestinal cancers.

GlycoNex Achieves PMDA Approval for First-in-Human Trial of GNX1021 Targeting Gastrointestinal Cancers #Japan #New_Taipei_City #GlycoNex #Cancer_Trials #GNX1021

GlycoNex Unveils Breakthrough Cancer Treatment at Major Conference in 2025 GlycoNex, a clinical-stage biotech firm, announces acceptance of its research on GNX1021 for presentation at an international cancer conference in Boston.

GlycoNex Unveils Breakthrough Cancer Treatment at Major Conference in 2025 #Taiwan #New_Taipei_City #ADC #GlycoNex #GNX1021

GlycoNex Showcases Promising Preclinical Findings for Novel ADC GNX1021 Targeting Gastric Cancer GlycoNex, Inc. announces success in preclinical trials of GNX1021, a pioneering ADC targeting gastric cancer, set to impact treatment options significantly.

GlycoNex Showcases Promising Preclinical Findings for Novel ADC GNX1021 Targeting Gastric Cancer #Taiwan #New_Taipei_City #ADC #GlycoNex #GNX1021

GlycoNex Introduces Promising GNX1021 Preclinical Results at AACR 2025 Meeting GlycoNex, a biotech firm, presents preclinical findings of GNX1021, a novel antibody-drug conjugate for gastric cancer, at AACR 2025.

GlycoNex Introduces Promising GNX1021 Preclinical Results at AACR 2025 Meeting #Taiwan #New_Taipei_City #biotech #GlycoNex #GNX1021

GlycoNex to Showcase Promising Preclinical Data on GNX1021 at AACR 2025 in Chicago GlycoNex, Inc. will reveal vital preclinical findings about its innovative anti-cancer drug GNX1021 at the upcoming AACR Annual Meeting 2025.

GlycoNex to Showcase Promising Preclinical Data on GNX1021 at AACR 2025 in Chicago #Taiwan #New_Taipei_City #Cancer_Research #GlycoNex #GNX1021